How This Former Weightlifter Lost 80 Pounds After GLP-1s Stopped Working

After trying diets and GLP-1 medications without lasting weight loss, former competitive weightlifter Dana Bichler (pictured above) lost more than 80 pounds following a minimally invasive procedure. Photo: Dana Bichler

Former competitive weightlifter Dana Bichler lost more than 80 pounds after undergoing endoscopic sleeve gastroplasty (ESG), a minimally invasive weight loss procedure.

After struggling with weight regain despite dieting and trying GLP-1 medications, Bichler pursued ESG amid concerns about his obesity-related fatty liver disease.

Bichler says the procedure helped him regain his energy, become more physically active, and enjoy activities with his family that had become difficult because of his weight.

For years, Dana Bichler was a competitive weightlifter. He felt fit and strong competing at 200 to 210 pounds. But wear and tear on his body and aging eventually pushed him to step away from weightlifting. Without the training, he began to gain weight slowly and steadily.

“I tried running, and a few other things, and the weight just crept up,” he told Healthline.

Dieting allowed him to lose about 50 pounds, but he would then regain it. At his heaviest, he weighed close to 300 pounds, which inspired him to visit a weight-loss clinic, where he followed a plan centered on the clinic’s foods.

“It’s a life of deprivation,” Bichler said. “You just can’t live like it.”

About five years ago, he tried a GLP-1 medication and two others a few years later. Each helped him lose weight initially but then stopped working.

“There was really no long-term positive effects or benefits that I saw,” he said.

However, he still takes Mounjaro for blood sugar control because he is prediabetic.

A few years ago, he was diagnosed with fatty liver disease. His condition was tied to obesity and caused scarring on his liver.

Bichler understood the seriousness of the condition as his two younger sisters and his oldest brother also had fatty liver disease. His brother and youngest sister developed cirrhosis, and his brother died after the disease affected other parts of his body.

“I had to do something,” he said. “What I was doing was not working.”

Why he chose endoscopic sleeve gastroplasty for weight loss

From his home in St. Cloud, Minnesota, Bichler traveled to the University of Minnesota to see a hepatologist, who referred him to a gastroenterologist who had worked with Boston Scientific on the instruments used to perform endoscopic sleeve gastroplasty (ESG).

ESG is a minimally invasive weight loss procedure performed using an FDA-authorized endoscopic suturing system, such as one offered through Boston Scientific’s Endura Weight Loss Solutions.

During ESG, a doctor passes an endoscope through the mouth and uses sutures to fold the stomach into a narrower sleeve. No portion of the stomach is removed, and there are no incisions. The smaller stomach limits how much a person can eat at once.

“Patients typically go home the same day and can return to routine daily activities within two to three days,” Brian Dunkin, MD, chief medical officer at Boston Scientific, told Healthline. “For the right person, that provides another less-invasive option to consider with their healthcare professional.”

While ESG may be a good option for some people who don’t achieve weight loss goals with GLP-1 medications, can’t tolerate them, or don’t want to stay on medication long term, Dunkin said he doesn’t think of it as ESG versus GLP-1 drugs.

“One of the best things GLP-1 medications have done is get more people talking to their doctors about obesity and recognizing it as a chronic disease that deserves treatment,” he said.

Each approach has different benefits, risks, and side effects.

“The goal is finding the right treatment, or combination of treatments, for the right patient at the right time,” said Dunkin.

ESG is indicated for adults with obesity with a BMI between 30 and 50, but Dunkin said BMI is only part of the conversation. ESG may be an option for people who aren’t getting the weight loss results they want, who don’t want to stay on weight loss medication long term, or for whom bariatric surgery may not be appropriate or desired, he added.

“Obesity is a chronic disease that requires long-term care,” said Dunkin. “ESG is one part of that care, which is why I believe so strongly in a multidisciplinary approach. The goal is to look at the whole person and find a care plan they can sustain over time.”

In March 2025, Bichler decided ESG was a good fit for him and received the procedure at Boston Scientific. At the time, he was 67 years old and on Medicare, which pre-approved the procedure.

“I just felt comfortable with it not being invasive, and I really needed to deal with [my weight], so I did,” he said.

How his life changed after endoscopic sleeve gastroplasty

When Bichler underwent ESG he weighed somewhere in the 260s. Today, he weighs 178 pounds.